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Single- and Multi-step selection studies were used to test the ability of BMS-284756,
ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin to yield resistant clones from
12 quinolone-susceptible and -resistant Streptococcus pneumoniae strains. Although all
quinolones selected, to a greater or lesser degree, for resistant clones with mutations
usually in parC or gyrA, BMS-284756 tended to select for resistant clones at a lower rate
than other quinolones studied.
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Infections caused by pneumococci with increased
MICs of penicillin G and other b-lactam and non-
b-lactam antibiotics have become a problem in
many parts of the world [1,2]. Previous studies
have documented a rate of penicillin resistance of
>30% in cases of complicated otitis media [3]. The
problem of drug-resistant pneumococci is compli-
cated by the ability of this organism to spread from
country to country, and from continent to conti-
nent [4,5].
Older fluoroquinolones such as ciprofloxacin
have marginal activity against Streptococcus pneu-
moniae. Although newer broader-spectrum quino-
lones are more active against these organisms,
toxicity has led to withdrawal of several of these
compounds. Currently, levofloxacin, gatifloxacin
and moxifloxacin are available for treatment of
infections caused by these organisms [6,7,9,10].
BMS-284756 (T-3811) is a new des-fluoroquino-
lone active against Gram-positive (including S.
pneumoniae) and -negative aerobes and anaerobes
[11,12]. Previous studies have documented MIC50
and MIC90 values against pneumococci of 0.03 and
0.06 mg/L, respectively, regardless of the strain’s
penicillin or macrolide susceptibility status [11].
If broad-spectrum quinolones are extensively
used for treatment of infections such as those in
the respiratory tract, particularly if the compounds
are eventually approved for use in children, a
selective pressure leading to resistance may occur.
A previous study from our laboratory has docu-
mented the capability of a variety of fluoroquino-
lones to select for resistant clones after multistep
subcultures in subinhibitory drug concentrations
[9]. This study attempted to shed further light on
this phenomenon by using single- and multistep
analyses to determine the capability of BMS-
284756 compared to ciprofloxacin, levofloxacin,
moxifloxacin and trovafloxacin to select for resis-
tance in 12 pneumococcal strains.
Twelve recent pneumococcal isolates were
selected for single- and multistep selection studies.
These include five strains with ciprofloxacin MICs
0.5–1.0 mg/L, five with ciprofloxacin MICs 8.0–
16.0 mg/L, and two with ciprofloxacin MICs of
32.0 mg/L. Organisms were identified by optochin
susceptibility and classified by serotyping. Strains
were stored at 70 8C in double-strength skim
milk (Difco Laboratories, Detroit, MI, USA) before
being tested. BMS-284756 susceptibility powder
was obtained from Bristol-Myers Squibb Labora-
tories (Wallingford, CT, USA): other drugs were
obtained from their respective manufacturers.
The breakpoints used were those of the National
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Committee for Clinical Laboratory Standards [13],
except for BMS-284756, where 1.0 mg/L was used.
For multistep studies, MICs were determined by
the standard broth microdilution method [13]
using cation-adjusted Mueller–Hinton broth
(BBL, Microbiology Systems, Cockeysville, MD,
USA) supplemented with 5% lyzed horse blood.
A final inoculum of 5 105 CFU/mL was used to
obtain mutants. Daily passages were then per-
formed for a maximum of 50 days by taking an
inoculum from the tube nearest the MIC (usually
1–2 dilutions below) that had the same turbidity as
the antibiotic-free controls. Subculturing was
stopped when mutants had BMS-284756 MICs
4 times the initial MIC, for ciprofloxacin and
levofloxacin when MICs were 8.0 mg/L or rose
to four times the initial MIC for strains with initial
MICs 8.0–32.0 mg/L, and for both trovafloxacin
and moxifloxacin when MICs were 4.0 mg/L or
rose to four times the MIC for strains with initial
MICs 2.0–4.0 mg/L (trovafloxacin) or 2.0 mg/L
(moxifloxacin). Irrespective of the number of sub-
cultures, passaging was stopped when the above
criteria were met, and strains were subcultured in
antibiotic-free medium for 10 serial passages.
Where no MIC increase occurred, a maximum of
50 serial passages in antibiotic was performed.
MICs of resistant mutants to all compounds were
tested in all combinations [8–10] (Table 1).
Results of multistep mutation analysis are pre-
sented in Table 1. The arithmetic mean of subcul-
ture days to obtain mutants from 12 strains were
20.8, 7, 34.3, 24.5 and 15.9 days for BMS-284756,
ciprofloxacin, levofloxacin, trovafloxacin and
moxifloxacin, respectively. From 12 strains, 54
mutants were selected by treatment with the five
antibiotics. Levofloxacin failed to select mutants
from four strains and trovafloxacin from two
strains. Among all selected mutants, 36 mutants
(66.6%) were susceptible to BMS-284756 (1.0 mg/
L), 17 mutants (31.4%) to trovafloxacin, 14 mutants
(25.9%) to moxifloxacin, and six strains to levo-
floxacin (11.1%). BMS-284756 was the most active
quinolone tested against selected mutants.
From all parent and selected strains, quinolone
resistance determined region (QRDR) fragments
of gyrA, gyrB, parC and parE genes were amplified
and sequenced as described previously [10].
Amino acid substitutions in the genes gyrA, gyrB,
parC and parE were determined by analyzing the
nucleotide sequences of their QRDR regions. Sub-
culturing in BMS-284756 selected 12 pneumococcal
strains with MICs 0.125–4.0 mg/L after 4–31 sub-
cultures. Treatment of five ciprofloxacin-suscepti-
ble strains (1, 2, 3, 4, 12) with BMS-284756 gave rise
to mutations in gyrB (L412H or R447H) in two
strains, and in gyrA (S81Y) in one strain. A mutant
from strain 12 had three mutations in parC, one
mutation in parE and an efflux mechanism. In total,
BMS-284756 selected four gyrA and three gyrB
mutations alone, one combination of mutations
in gyrA and parE, and one combination of three
parC mutations and one parE mutation. For three
mutants selected by BMS-284756, no difference
from the parent strain was found in the QRDR
of gyrA, gyrB, parC or parE. Six mutants with
quinolone-resistant parents had BMS-284756 MICs
4.0 mg/L. Four were selected by moxifloxacin:
(1) strain 5, whose parent had S79F in parC and
developed S81F in gyrA; (2) strain 6, whose parent
had S79F in parC and developed S81F and E85Y in
gyrA; (3) strain 7, whose parent had D83N and
K137N in parC and I460V in parE and developed
S81A in gyrA; and (4) strain 8, whose parent had
S79F and K137N in parC, I460V in parE and E474K
in gyrB and developed four amino acid deletions in
gyrB. The BMS-284756 MICs of these mutants were
4.0–8.0 mg/L. Levofloxacin selected one mutant
from strain 10 with S79F in parC and S81C in gyrA
that then developed D83N in parC and E85K in
gyrA. This strain had the highest BMS-284756 MIC
(16.0 mg/L). From the same strain, BMS-284756
selected a mutant with MIC 4.0 mg/L that devel-
oped E85K in gyrA.
Six of the mutants selected by moxifloxacin had
alterations in gyrB, and one mutant had four amino
acid deletions, two mutants had three amino acid
substitutions, and three mutants had one amino
acid substitution.
The effects of efflux on parent and mutant
strains are shown in Table 1. Except for ciproflox-
acin, other antibiotics were less affected by efflux.
Three mutants had four-fold lower MICs for BMS-
284756, and two mutants for levofloxacin in the
presence of reserpine.
Single-step mutation rates at the MIC were
tested for the 12 parent strains (Table 2). For five
strains with MICs (mg/L) of 0.03 (BMS-284756),
0.5–1.0 (ciprofloxacin, levofloxacin), and 0.06–0.125
(trovafloxacin, moxifloxacin), mutation frequencies
at the MIC were: 1.0 104 to <1.0 1010 (BMS-
284756); >3.0 101 to 2.5 106 (ciprofloxacin);
3.3 105 to 3.5 106 (levofloxacin); 1.9 102 to
2.0 107 (trovafloxacin); 1.7 105 to 1.0 107
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Table 1 The results of multistep resistance selection for BSM-284756, ciprofloxacin, levofloxacin, trovafloxacin, and moxifloxacin
Initial MIC (mg/L)
before exposure to drug
MICs (mg/L)
of resistant mutantsa
Mutations in QRDR
of resistant mutantsc
Strain BMS CIP LEV TVA MOX
No. of
passages
Selecting
agents BMS CIP LEV TVA MOX ParC GyrA ParE GyrB
1 0.03 1 1 0.12 0.12 31 BMS 0.125 1b 1 0.125 0.25 – – – L412H
7 CIP 0.125 4b 2 0.25 0.25 – – – –
50 LEV – – – –
24 TVA 1 16 16 4 4 S79A S81Y R447C –
41 MOX 1 16b 16 1 4 – – D435N G406S, S438Y,
E474K
2 0.03 1 1 0.12 0.12 29 BMS 0.25 4 2 0.5 1 – S81Y – –
4 CIP 0.25 4b 4 0.125 0.25 – – – –
50 LEV – – – –
33 TVA 1 16 16 4 8 S79F S81Y – –
35 MOX 1 16 8 1 4 S79Y – L431I G406C, R445G,
P454S
3 0.03 0.5 1 0.06 0.12 13 BMS 0.25 0.5 2 0.25 0.25 D83N S81Y – –
7 CIP 0.25 8b 4 0.5 1 S79Y – – –
36 LEV 0.5 32 8 2 2 – – G410D –
50 TVA – – – –
9 MOX 1 32 32 2 4 S79Y – – D435N
4 0.03 1 1 0.06 0.13 29 BMS 0.125 1 1 0.125 0.25 – – – R447H
16 CIP 0.125 8b 1 0.25 0.25 – – – –
48 LEV 1 32 16 8 16 D83N S81Y – –
50 TVA – – – –
25 MOX 1 8 4 1 2 – S81Y – –
5 0.03 16b 1 0.25 0.5 14 BMS 2 16 32 8 4 (S79F) E85K – –
4 CIP 1 64b 32 4 4 (S79F) S81F – –
12 LEV 1 32 16 8 4 (S79F) S81F – –
4 TVA 1 64b 32 4 4 (S79F) S81F – –
5 MOX 4 128b 64 8 8 (S79F) S81F – –
6 0.06 16b 4 0.25 0.5 12 BMS 2 128 32b 4 4 (S79F) S81F – –
4 CIP 2 64b 32 4 4 (S79F) S81F – –
18 LEV 0.5 64 16 1 0.5 (S79F) – – –
4 TVA 1 64b 32 4 4 (S79F) S81F – E474K
5 MOX 8 128b 64 8 16 (S79F) S81F,
E85Y
– –
7 0.12 8b 4 0.25 0.5 29 BMS 1b 32 32b 1 1 (D83N)
(K137N)
– (I460V) –
4 CIP 2 64b 32 1 2 (D83N)
(K137N)
S81Y (I460V) –
19 LEV 2b 64 32 4 4 (D83N)
(K137N)
S81Y (I460V),
E474K
–
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Table 1 continued
Initial MIC (mg/L)
before exposure to drug
MICs (mg/L)
of resistant mutantsa
Mutations in QRDR
of resistant mutantsc
Strain BMS CIP LEV TVA MOX
No. of
passages
Selecting
agents BMS CIP LEV TVA MOX ParC GyrA ParE GyrB
30 TVA 1 128b 16 2 1 (D83N) (K137N),
S79F
– (I460V) –
14 MOX 4 64b 16 2 2 (K137N) S81A (D83N) (I460V) –
8 0.12 8 4 0.5 0.5 4 BMS 1 32 32 8 4 (S79F) (K137N) S81Y (I460V),
V460I
(E474K)
6 CIP 0.25 64b 16 1 0.5 (S79F) (K137N) – (I460V) (E474K)
16 LEV 1 32 16 8 4 (S79F) (K137N) E85G (I460V) (E474K)
5 TVA 2 16 16 2 2 (S79F) (K137N) – (I460V) (E474K)
7 MOX 8 32 16 4 4 (S79F) (K137N) – (I460V) (E474K) Del
411NLPG
9 0.25 16 8 2 2 16 BMS 2 16 8 2 2 – (S81F) (I460V) –
4 CIP 1 64b 32 2 4 – (S81F) (I460V) –
36 LEV 1 64 128 4 4 – (S81F) (I460V),
D434N
D435G
5 TVA 0.5 16 16 2 2 – (S81F) (I460V) –
5 MOX 1 32 16 4 4 – (S81F) (I460V) –
10 0.25 32 8 2 1 17 BMS 4 64 16 64 64 (S79F) (S81C),
E85K
– –
13 CIP 1 64b 16 2 2 (S79F) (S81C) – –
27 LEV 16 64 128 16 64 (S79F), D83N (S81C),
E85K
– –
5 TVA 0.5 32b 16 4 2 (S79F) (S81C),
V71I
– –
13 MOX 2 64 16 4 2 (S79F) (S81C) – K404I
11 0.25 32 8 4 2 27 BMS 2 128 32 2 4 (D83N) (S81F) – P413L
8 CIP 1 64b 16 2 2 (D83N) (S81F) – –
50 LEV (D83N) (S81F) – –
40 TVA 2 64 32 8 4 (D83N), S79F (S81F) – –
7 MOX 2 64b 16 4 4 (D83N) (S81F) – –
12 0.03 1 0.5 0.06 0.12 29 BMS 1b 32b 8 0.5 1 S79F, D83N, K137N I460V –
7 CIP 0.125 8b 4 0.25 0.25 – – – –
50 LEV – – – –
45 TVA 1 32b 16 2 4 D83N S81F – –
25 MOX 2 64b 16 2 4 D83N S81F – P454S
aMICs determined after 10 days of antibiotic-free subculture. bAt least a four-fold decrease in MIC in the presence of reserpine defined as efflux mechanism. cDashes
mean ‘no mutation’. The mutations found in the parent strains are shown in parentheses. New mutations in mutant strains are shown in bold type. BMS, BMS-284756;
CIP, ciprofloxacin; LEV, levofloxacin; TVA, trovafloxacin; MOX, moxifloxacin.
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Table 2 Frequency of single-step mutations for the same12 S. pneumoniae parent strains as in Table 1. Single-step mutants from strain 3 and strain 10 were analyzed for
alterations in QRDR.
Strain Selecting agent Initial MIC (mg/L) 1MIC 2MIC 4MIC 8MIC 16MIC
1 BMS-284756 0.03 <1.0 1010 <1.0 1010 <1.0 1010 <1.0 1010 <1.0 1010
Ciprofloxacin 1 >3.0 101 3.2 104 4.6 107 <1.0 1010 <1.0 1010
Levofloxacin 1 3.5 106 <1.0 1010 <1.0 1010 <1.0 1010 <1.0 1010
Trovafloxacin 0.125 1.9 103 7.0 107 3.0 109 <1.0 1010 <1.0 1010
Moxifloxacin 0.125 1.0 106 <1.0 1010 <1.0 1010 <1.0 1010 <1.0 1010
2 BMS-284756 0.03 <5.9 109 <5.9 109 <5.9 109 <5.9 109 <5.9 109
Ciprofloxacin 1 1.4 102 1.2 106 4.0 109 <2.0 1010 <2.0 1010
Levofloxacin 1 5.9 106 <5.9 109 <5.9 109 <5.9 109 <5.9 109
Trovafloxacin 0.125 3.2 104 6.6 107 <2.0 1010 <2.0 1010 <2.0 1010
Moxifloxacin 0.125 1.5 106 <1.0 1010 <1.0 1010 <1.0 1010 <1.0 1010
3 BMS-284756 0.03 9.1 107 <9.1 109 <9.1 109 <9.1 109 <9.1 109
Ciprofloxacin 0.5 4.2 103 6.0 106 2.0 108 <3.3 109 <3.3 109
Levofloxacin 1 3.8 106 <1.3 108 <1.3 108 <1.3 108 <1.3 108
Trovafloxacin 0.06 1.9 102 1.5 105 3.0 107 <3.3 109 <3.3 109
Moxifloxacin 0.125 1.5 105 2.5 108 <5.0 109 <5.0 109 <5.0 109
4 BMS-284756 0.03 1.0 104 <1.0 108 <1.0 108 <1.0 108 <1.0 108
Ciprofloxacin 1 2.5 106 1.3 108 <2.5 1010 <2.5 1010 <2.5 1010
Levofloxacin 1 3.3 105 <1.7 108 <1.7 108 <1.7 108 <1.7 108
Trovafloxacin 0.06 2.0 107 2.3 108 <2.5 1010 <2.5 1010 <2.5 1010
Moxifloxacin 0.125 1.7 105 <1.0 1010 <1.0 1010 <1.0 1010 <1.0 1010
5 BMS-284756 0.03 1.5 106 6.5 107 1.5 107 3.0 109 <5.0 1010
Ciprofloxacin 16 2.0 105 1.0 105 <1.7 109 <1.7 109 <1.7 109
Levofloxacin 1 5.0 105 8.0 107 6.0 107 2.0 108 3.5 109
Trovafloxacin 0.25 4.5 104 1.5 105 1.3 105 6.0 106 <1.7 109
Moxifloxacin 0.5 4.5 105 7.0 106 4.3 106 2.8 107 <1.7 109
6 BMS-284756 0.06 6.7 106 1.0 106 3.0 107 1.5 107 <3.3 1010
Ciprofloxacin 16 2.5 105 1.5 106 <1.0 1010 <1.0 1010 <1.0 1010
Levofloxacin 4 2.2 106 7.8 107 7.8 107 2.8 108 <1.1 109
Trovafloxacin 0.25 3.0 105 2.0 106 <1.0 1010 <1.0 1010 <1.0 1010
Moxifloxacin 0.5 1.2 107 <1.0 1010 <1.0 1010 <1.0 1010 <1.0 1010
7 BMS-284756 0.125 3.0 106 1.0 107 <2.5 109 <2.5 109 <2.5 109
Ciprofloxacin 8 2.3 106 2.4 107 3.3 109 <3.3 1010 <3.3 1010
Levofloxacin 4 1.8 106 5.3 107 <2.5 109 <2.5 109 <2.5 109
Trovafloxacin 0.25 1.0 106 1.4 107 1.0 108 <3.3 1010 <3.3 1010
Moxifloxacin 0.5 2.8 106 1.0 106 7.5 108 <1.0 1010 <1.0 1010
8 BMS-284756 0.125 5.0 105 <1.7 108 <1.7 108 <1.7 108 <1.7 108
Ciprofloxacin 8 1.6 104 3.0 107 <1.0 109 <1.0 109 <1.0 109
Levofloxacin 4 8.9 103 <1.1 108 <1.1 108 <1.1 108 <1.1 108
Trovafloxacin 0.5 1.0 105 1.0 106 3.5 107 <1.0 109 <1.0 109
Moxifloxacin 0.5 2.2 106 2.1 107 4.6 108 <1.0 1010 <1.0 1010
9 BMS-284756 0.25 2.5 103 3.3 107 <1.7 109 <1.7 109 <1.7 109
Ciprofloxacin 16 8.0 104 <2.0 109 <2.0 109 <2.0 109 <2.0 109
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(moxifloxacin). For five strains with MICs (mg/L)
of 0.03–0.25 (BMS-284756), 8.0–16.0 (ciprofloxacin),
1.0–8.0 (levofloxacin), 0.25–2.0 (trovafloxacin), and
0.5–2.0 (moxifloxacin), mutation frequencies at the
MIC were: 2.5 103 to 1.5 106 (BMS-284756);
8.0 104 to 2.3 106 (ciprofloxacin); 1.0 102 to
1.8 106 (levofloxacin); 4.5 104 to <2.0 109
(trovafloxacin); 4.5 105 to <2.0 109 (moxi-
floxacin). For two strains with MICs (mg/L) of
0.25 (BMS-284756), 32.0 (ciprofloxacin), 8.0 (levo-
floxacin), 2.0–4.0 (trovafloxacin), and 1.0–2.0 (mox-
ifloxacin), mutation frequencies at the MIC were:
1.6 105 to 1.0 105 (BMS-284756); 1.7 103 to
3.6 104 (ciprofloxacin); 3.0 104 to 4.4 109
(levofloxacin); 4.4 106 to 3.0 106 (trovafloxa-
cin); 3.0 104 to 4.0 105 (moxifloxacin). BMS-
284756 had the lowest MICs and overall resistance
selection rates of all quinolones tested. Among
clones selected by single-step methodology,
mutants from strains 3 and 10 were analyzed for
alterations in QRDR of parC, gyrA, parE and gyrB.
Mutants selected from strain 10 by 2MIC of
trovafloxacin had a C81W mutation in gyrA; those
selected by MIC and 2MIC of moxifloxacin had
L412R and P454S mutations in gyrB.
All resistant clones showed pulsed-field pat-
terns identical to those of their parents. Selected
clones were either serologically identical to their
parents or had lost their capsules due to multiple
subculturing.
Time–kill studies showed that BMS-284756, at
24 h and two times the MIC, was bactericidal
(99.9% killing) against all four strains tested, with
lower (but detectable) killing rates at earlier time
periods (Figure 1).
BMS-284756 [11,12] is a new quinolone
with a broad spectrum of activity against Gram-
positive organisms (including pneumococci and
quinolone-susceptible staphylococci), Enterobac-
teriaceae,acinetobacters, legionellasandmycoplas-
mas. The drug is less active against Pseudomonas
aeruginosa. Takahata et al. [11] have reported BMS-
284756 MIC50 and MIC90 values of 0.025–0.05 and
0.05 mg/L for penicillin-susceptible, -intermediate
and -resistant strains, respectively; BMS-284756
MICs were at least one log lower than those of
ciprofloxacin and levofloxacin, with MICs one dilu-
tion lower than those for trovafloxacin. These MICs
are similar to those found in the current study, as
well as in the study by Fung-Tomc et al. [12].
BMS-284756 and moxifloxacin gave rise to
mutations in gyrB which were associated withT
ab
le
2
co
n
ti
n
u
ed
S
tr
ai
n
S
el
ec
ti
n
g
ag
en
t
In
it
ia
l
M
IC
(m
g
/L
)
1

M
IC
2

M
IC
4

M
IC
8

M
IC
16

M
IC
L
ev
o
fl
o
x
ac
in
8
1.
0

10

2
<
1.
0

10

8
<
1.
0

10
8
<
1.
0

10
8
<
1.
0

10
8
T
ro
v
af
lo
x
ac
in
2
<
2.
0

10

9
<
2.
0

10

9
<
2.
0

10
9
<
2.
0

10
9
<
2.
0

10
9
M
o
x
if
lo
x
ac
in
2
<
2.
0

10

9
<
2.
0

10

9
<
2.
0

10
9
<
2.
0

10
9
<
2.
0

10
9
10
B
M
S
-2
84
75
6
0.
25
1.
6

10

5
<
4.
0

10

9
<
4.
0

10
9
<
4.
0

10
9
<
4.
0

10
9
C
ip
ro
fl
o
x
ac
in
32
1.
7

10

3
1.
5

10

6
<
1.
0

10
9
<
1.
0

10
9
<
1.
0

10
9
L
ev
o
fl
o
x
ac
in
8
4.
4

10

9
<
4.
0

10

9
<
4.
0

10
9
<
4.
0

10
9
<
4.
0

10
9
T
ro
v
af
lo
x
ac
in
2
3.
0

10

6
8.
0

10

7
<
1.
0

10
9
<
1.
0

10
9
<
1.
0

10
9
M
o
x
if
lo
x
ac
in
1
4.
0

10

5
1.
0

10

6
<
1.
0

10
9
<
1.
0

10
9
<
1.
0

10
9
11
B
M
S
-2
84
75
6
0.
25
1.
0

10

5
<
1.
7

10

8
<
1.
7

10
8
<
1.
7

10
8
<
1.
7

10
8
C
ip
ro
fl
o
x
ac
in
32
3.
6

10

4
2.
0

10

8
<
2.
0

10
8
<
2.
0

10
8
<
2.
0

10
8
L
ev
o
fl
o
x
ac
in
8
3.
0

10

4
1.
3

10

7
<
5.
0

10
9
<
5.
0

10
9
<
5.
0

10
9
T
ro
v
af
lo
x
ac
in
4
4.
4

10

6
9.
0

10

7
2.
2

10
7
<
2.
0

10
8
<
2.
0

10
8
M
o
x
if
lo
x
ac
in
2
3.
0

10

4
<
2.
0

10

8
<
2.
0

10
8
<
2.
0

10
8
<
2.
0

10
8
12
B
M
S
-2
84
75
6
0.
03
<
5.
0

10

1
0
<
5.
0

10

1
0
<
5.
0

10
1
0
<
5.
0

10
1
0
<
5.
0

10
1
0
C
ip
ro
fl
o
x
ac
in
1
>
2.
3

10

2
2.
8

10

5
<
7.
7

10
9
<
7.
7

10
9
<
7.
7

10
9
L
ev
o
fl
o
x
ac
in
0.
5
1.
0

10

5
4.
0

10

8
<
3.
3

10
9
<
3.
3

10
9
<
3.
3

10
9
T
ro
v
af
lo
x
ac
in
0.
06
9.
2

10

4
9.
2

10

7
1.
2

10
7
<
7.
7

10
9
<
7.
7

10
9
M
o
x
if
lo
x
ac
in
0.
12
5
1.
0

10

7
<
7.
7

10

9
<
7.
7

10
9
<
7.
7

10
9
<
7.
7

10
9
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 373–380
378 Clinical Microbiology and Infection, Volume 8 Number 6, June 2002
increases in MICs for both antibiotics. This sug-
gests that the protein GyrB may be a target of these
antibiotics. Analysis of mutations in selected
clones showed affinity of all quinolones tested to
type II topoisomerase: for BMS-284756, affinity
was highest for the protein GyrA, followed by
GyrB; for levofloxacin, targets were the proteins
GyrA and ParE, for moxifloxacin, proteins GyrA
and GyrB, and for trovafloxacin, proteins GyrA
and ParC. The above-mentioned targets may be
primary or secondary [14,15]. Results also indicate
that BMS-284756 is most affected by double muta-
tions in gyrA at positions Ser81 and Glu85 and
deletion in gyrB. These findings require confirma-
tion by examination of more laboratory and clin-
ical strains.
We found that all quinolones tested, to a greater
or lesser degree, selected for resistant clones with
identical mutations, usually in parC or gyrA, to
those seen in clinical strains [9,14,15]. However,
several clones with raised quinolone MICs but no
detectable quinolone resistance mechanism were
detected in the current study. The possibility of
mutations in areas outside the QRDRs is currently
being investigated. In this as well as a previous
study [10], we found frequencies of single-step
resistance to vary among strains with the same
initial MICs by up to five orders of magnitude. The
reason for this is unknown at present and is also
being studied.
Recent reports from Hong Kong [17], Canada
[18] and Spain [19] have documented a worrisome
trend towards increased pneumococcal quinolone
MICs. Results from this and other MIC studies
show that not only has BMS-284756 excellent
in vitro antipneumococcal activity, but that its
tendency to select for resistant clones is lower
than that of other quinolones tested in this study.
A C K N O W L E D G M E N T S
This study was supported by a grant from
Bristol-Myers Squibb Laboratories, Wallingford,
CT, USA.
R E F E R E N C E S
1. Appelbaum PC. Antimicrobial resistance in Strep-
tococcus pneumoniae—an overview. Clin Infect Dis
1992; 15: 77–83.
2. Jacobs MR, Appelbaum PC. Antibiotic-resistant
pneumococci. Rev Med Microbiol 1995; 6: 77–93.
3. Block S, Harrison CJ, Hedrick JA et al. Penicillin-
resistant Streptococcus pneumoniae in acute otitis
media: risk factors, susceptibility patterns and
antimicrobial management. Pediatr Infect Dis J
1995; 14: 751–9.
4. McDougal LK, Facklam R, Reeves M et al. Analysis
of multiply antimicrobial-resistant isolates of Strep-
tococcus pneumoniae from the United States. Anti-
microb Agents Chemother 1992; 36: 2176–84.
5. Munoz R, Musser JM, Crain M et al. Geographic
distribution of penicillin-resistant clones of Strepto-
coccus pneumoniae: characterization by penicillin-
binding protein profile, surface protein A typing,
and multilocus enzyme analysis. Clin Infect Dis
1992; 15: 112–18.
6. Friedland IR, McCracken GH Jr. Management of
infections caused by antibiotic-resistant Streptococ-
cus pneumoniae. N Engl J Med 1994; 331: 377–82.
7. Pankuch GA, Jacobs MR, Appelbaum PC. Study of
comparative antipneumococcal activities of penicil-
lin G, RP 59500, erythromycin, sparfloxacin, cipro-
floxacin and vancomycin by using time-kill
Figure 1 Time kill results, at two
times the MIC, of four BMS-284756
resistant clones with MICs of 2 mg/L.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 373–380
Concise Communication 379
methodology. Antimicrob Agents Chemother 1994; 38:
2065–72.
8. Pankuch GA, Jueneman SA, Davies TA, Jacobs MR,
Appelbaum PC. In vitro selection of resistance to
four b-lactams and azithromycin in Streptococcus
pneumoniae. Antimicrob Agents Chemother 1998; 42:
2914–18.
9. Davies TA, Pankuch GA, Dewasse BE, Jacobs MR,
Appelbaum PC. In vitro development of resistance
to five quinolones and amoxicillin–clavulanate in
Streptococcus pneumoniae. Antimicrob Agents Che-
mother 1999; 43: 1177–82.
10. Nagai K, Davies TA, Pankuch GA, Dewasse BE,
Jacobs MR, Appelbaum PC. In vitro selection of
resistance to clinafloxacin, ciprofloxacin and trova-
floxacin in Streptococcus pneumoniae. Antimicrob
Agents Chemother 2000; 44: 2740–6.
11. Takahata M, Mitsuyama J, Yamashiro Y et al. In
vitro and in vivo antimicrobial activities of T-
3811ME, a novel Des-F(6)-quinolone. Antimicrob
Agents Chemother 1999; 43: 1077–84.
12. Fung-Tomc JC, Minassian B, Kolek B et al. Anti-
bacterial spectrum of a novel des-fluoro(6) quino-
lone, BMS-284756. Antimicrob Agents Chemother
2000; 44: 3351–6.
13. National Committee for Clinical Laboratory Stan-
dards. Methods for dilution antimicrobial susceptibility
tests for bacteria that grow aerobically, 3rd edn.
Approved standard. NCCLS publication no. M7-
A4. Wayne, Pa: NCCLS, 1997.
14. Pan XS, Ambler J, Mehtar S, Fisher LM. Involve-
ment of topoisomerase IV and DNA gyrase as
ciprofloxacin targets in Streptococcus pneumoniae.
Antimicrob Agents Chemother 1996; 40: 2321–6.
15. Pan XS, Fisher LM. DNA gyrase and topoisomerase
IV are dual targets of clinafloxacin action in Strepto-
coccus pneumoniae. Antimicrob Agents Chemother 1998;
42: 2810–16.
16. Brenwald NP, Gill MJ, Wise R. Prevalence of a
putative efflux mechanism among fluoroquinolone-
resistant clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother 1998; 42: 2032–5.
17. Ho P-L, Que T-L, Chang DN-C, Ng T-K, Chow K-C,
Seto W-H. Emergence of fluoroquinolone resistance
among multiply resistant strains of Streptococcus
pneumoniae in Hong Kong. Antimicrob Agents Che-
mother 1999; 43: 1310–13.
18. Chen DK, McGeer A, de Azavedo JC, Low DE.
Decreased susceptibility of Streptococcus pneumoniae
to fluoroquinolones in Canada. N Engl J Med 1999;
341: 233–9.
19. Lin˜ares J, de la Campa AG, Pallares R. Fluoroqui-
nolone resistance in Streptococcus pneumoniae. N
Engl J Med 1999; 341: 1546–7.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 373–380
380 Clinical Microbiology and Infection, Volume 8 Number 6, June 2002
